Rawia Mohamed/LinkedIn
Jun 24, 2025, 06:49
Rawia Mohamed: UAE’s First Claudin 18.2 IHC Testing for Gastric Cancers Launches at Burjeel Medical City
Rawia Mohamed, Head of the Anatomical Pathology Department at Burjeel Medical City, shared a post on LinkedIn:
“In a groundbreaking advancement for cancer diagnostics in the region, the Anatomical Pathology Laboratory at Burjeel Holdings has become the first laboratory in the UAE and the Middle East to offer Claudin 18.2 immunohistochemistry (IHC) testing for gastric and advanced gastroesophageal adenocarcinomas.
Claudin 18.2 is an emerging companion diagnostic marker critical for identifying patients who may benefit from targeted therapies in the treatment of gastric cancers. Its clinical relevance has grown with the development of monoclonal antibody-based treatments aimed at Claudin 18.2-positive tumors—offering new hope for patients with limited treatment options.
“Integrating Claudin 18.2 testing into our diagnostic portfolio not only strengthens our commitment to precision oncology, but also positions our laboratory at the forefront of personalized cancer care in the region,” said Dr. Rawia Mubarak Mohamed, Head of the Anatomical Pathology Department. “This milestone reflects our continued pursuit of innovation and reinforces our role as leaders in advanced diagnostic services.”
The introduction of Claudin 18.2 testing aligns with global precision medicine strategies, where biomarker-driven therapy selection ensures that each patient receives the most effective, targeted treatment. As a companion diagnostic, Claudin 18.2 supports clinical decision-making by identifying eligible patients for clinical trials and approved targeted therapies, enabling more tailored and effective treatment plans.
This advancement underscores Burjeel Holdings role in enhancing diagnostic capabilities across the UAE and the wider Middle East, with a strong focus on translational medicine and collaborative oncology care.”
Rawia Mohamed announced that Burjeel Medical City is the first in the UAE and Middle East to implement Claudin 18.2 IHC testing for gastric and gastroesophageal cancers.
She emphasized its value in precision oncology and the growing role of biomarker-based therapies in regional cancer care.”
More posts featuring Gastric Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 24, 2025, 06:41
Jun 24, 2025, 06:31
Jun 24, 2025, 06:02
Jun 24, 2025, 05:47